Literature DB >> 11166146

Radiation therapy alone or combined surgery and radiation therapy in squamous-cell carcinoma of the penis?

A Zouhair1, P A Coucke, W Jeanneret, P Douglas, H P Do, P Jichlinski, R O Mirimanoff, M Ozsahin.   

Abstract

To assess the prognostic factors and the outcome in patients with squamous-cell carcinoma of the penis, a retrospective review of 41 consecutive patients with non-metastatic invasive carcinoma of the penis, treated between 1962 and 1994, was performed. The median age was 59 years (range: 35-76 years). According to the International Union Against Cancer (UICC) 1997 classification, there were 12 (29%) T1, 24 (59%) T2, 4 (10%) T3 and 1 TX (2%) tumours. The N-classification was distributed as follows: 29 (71%) patients with N0, 8 (20%) with N1, 3 (7%) with N2 and 1 (2%) with N3. Forty-four per cent (n=18) of the patients underwent surgery: partial penectomy with (n=4) or without (n=12) lymph node dissection, or total penectomy with (n=1) or without (n=1) lymph node dissection. 23 patients were treated with radiation therapy alone, and all but 4 of the patients who were operated upon received postoperative radiation therapy (n=14). The median follow-up period was 70 months (range 20-331 months). In a median period of 12 months (range 5-139 months), 63% (n=26) of the patients relapsed (local in 18, locoregional in 2, regional in 3 and distant in 3). Local failure (stump in the operated patients, and the tumour bed in those treated with primary radiation therapy) was observed in 4 out of 16 (25%) patients treated with partial penectomy +/-postoperative radiotherapy versus 14 out of 23 (61%) treated with primary radiotherapy (P=0.06). 15 (83%) out of 18 local failures were successfully salvaged with surgery. In all patients, 5- and 10-year survival rates were 57% (95% confidence interval (CI), 41-73%) and 38% (95% CI, 21-55%), respectively. The 5-year local and locoregional rates were 57% (95% CI, 41-73%) and 48% (95% CI, 32-64%), respectively. In patients treated with primary radiotherapy, 5- and 10-year probabilities of surviving with penis preservation were 36% (95% CI, 22-50%) and 18% (95% CI, 2-34%), respectively. In multivariate analyses, survival was significantly influenced by the N-classification, and surgery was the only independent factor predicting the locoregional control. We conclude that, in patients with squamous-cell carcinoma of the penis, local control is better in patients treated with surgery. However, there seems to be no difference in terms of survival between patients treated by surgery and those treated by primary radiotherapy +/-salvage surgery, with 39% having organ preservation.

Entities:  

Mesh:

Year:  2001        PMID: 11166146     DOI: 10.1016/s0959-8049(00)00368-3

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  15 in total

Review 1.  Penile cancer: current therapy and future directions.

Authors:  G Sonpavde; L C Pagliaro; C Buonerba; T B Dorff; R J Lee; G Di Lorenzo
Journal:  Ann Oncol       Date:  2013-01-04       Impact factor: 32.976

Review 2.  Organ Preservation Surgery for Carcinoma Penis.

Authors:  T B Yuvaraja; Santosh Waigankar; Nikhil Dharmadhikari; Abhinav Pednekar
Journal:  Indian J Surg Oncol       Date:  2016-12-20

Review 3.  Current trends in the management of carcinoma penis--a review.

Authors:  Iqbal Singh; A Khaitan
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

4.  Radiation therapy in the management of the primary penile tumor: an update.

Authors:  Juanita Crook; Clement Ma; Laval Grimard
Journal:  World J Urol       Date:  2008-07-18       Impact factor: 4.226

5.  Penile cancer: Clinical Practice Guidelines in Oncology.

Authors:  Peter E Clark; Philippe E Spiess; Neeraj Agarwal; Matthew C Biagioli; Mario A Eisenberger; Richard E Greenberg; Harry W Herr; Brant A Inman; Deborah A Kuban; Timothy M Kuzel; Subodh M Lele; Jeff Michalski; Lance Pagliaro; Sumanta K Pal; Anthony Patterson; Elizabeth R Plimack; Kamal S Pohar; Michael P Porter; Jerome P Richie; Wade J Sexton; William U Shipley; Eric J Small; Donald L Trump; Geoffrey Wile; Timothy G Wilson; Mary Dwyer; Maria Ho
Journal:  J Natl Compr Canc Netw       Date:  2013-05-01       Impact factor: 11.908

6.  [Focal therapy for penile cancer].

Authors:  O W Hakenberg; C Protzel
Journal:  Urologe A       Date:  2016-05       Impact factor: 0.639

7.  The Diagnosis and Treatment of Penile Cancer.

Authors:  Oliver Walther Hakenberg; Desiree Louise Dräger; Andreas Erbersdobler; Carsten Maik Naumann; Klaus-Peter Jünemann; Chris Protzel
Journal:  Dtsch Arztebl Int       Date:  2018-09-28       Impact factor: 5.594

8.  Survival Following Salvage Surgery after Failed Radiotherapy for Penile Cancer: A SEER-Based Study.

Authors:  Mahmoud I Khalil; Fei Wan; Ehab Eltahawy; Rodney Davis; Philippe E Spiess; Nabil K Bissada; Mohamed H Kamel
Journal:  Curr Urol       Date:  2019-05-10

9.  Intrinsic radiosensitivity, genomic-based radiation dose and patterns of failure of penile cancer in response to adjuvant radiation therapy.

Authors:  Zhigang Yuan; G Daniel Grass; Mounsif Azizi; Kamran A Ahmed; G Sean J Yoder; Eric A Welsh; William J Fulp; Jasreman Dhillon; Javier F Torres-Roca; Anna R Giuliano; Philippe E Spiess; Peter A Johnstone
Journal:  Rep Pract Oncol Radiother       Date:  2019-11-01

10.  Comparison of efficacy between brachytherapy and penectomy in patients with penile cancer: a meta-analysis.

Authors:  Xiheng Hu; Jianghai Huang; Sailan Wen; Jun Fu; Minfeng Chen
Journal:  Oncotarget       Date:  2017-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.